Know Cancer

forgot password

Basal Cell Carcinoma Recurrence

18 Years
Not Enrolling
Basal Cell Carcinoma

Thank you

Trial Information

Basal Cell Carcinoma Recurrence

Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States,
affecting nearly one million of all Americans. While BCC is rarely mortal, it has
significant associated physical, psychological, and monetary costs to patients such as
disfigurement and sensory loss. Individuals who have been diagnosed with at least one BCC
lesion are likely to be diagnosed with more in the future. Treatment of these lesions and
recurrent physician appointments can be a great inconvenience to patients, resulting in
expenses to patients and loss of work and family time.

The Mohs surgery technique is associated with a low recurrence rate for BCC and is preferred
for higher risk tumors and for tumors in cosmetically sensitive sites on the head and neck.
While recurrence rates of BCC post Mohs are 1-2% for primary basal cells, recent data is not
available to validate this historical assessment. Currently, comprehensive rates of
recurrence are not available because a national registry of recurrence rates for BCC and
squamous cell carcinoma (SCC) does not exist.

The purpose of this study is to both historically and prospectively assess current basal
cell carcinoma recurrence rates in patients undergoing Mohs micrographic surgery.

Inclusion Criteria:

- Subjects with BCC lesions on the head, neck, genitalia, hands, or feet

- Subjects who have undergone Mohs micrographic surgery for BCC on or before December
31, 2006

- Subjects with a medical record at the respective site

- Subjects in a stable health condition, as determined by the principle investigator

Exclusion Criteria:

- Subjects with basal cell nevus syndrome

- Subjects with lesions only in areas other than the head, neck, genitalia,

- hands and feet

- Subjects who have not followed up through the Department of Dermatology

- Subjects with recurrent BCC lesions diagnosed on or prior to the recorded date of
Mohs surgery

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Recurrence of BCC

Outcome Time Frame:

either after 1 study visit (historical arm), or 3 years (prospective arm)

Safety Issue:


Principal Investigator

Murad Alam, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Northwestern University


United States: Institutional Review Board

Study ID:




Start Date:

May 2008

Completion Date:

May 2009

Related Keywords:

  • Basal Cell Carcinoma
  • Skin Cancer
  • Basal Cell
  • Mohs surgery
  • Carcinoma
  • Carcinoma, Basal Cell
  • Recurrence



DuPage Medical Group Dermatology Naperville, Illinois  60563
Northwestern University Feinberg School of Medicine, Department of Dermatology Chicago, Illinois  60611